Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | Rilotumumab |
Trade Name | |
Synonyms | AMG102|AMG-102 |
Drug Descriptions |
Rilotumumab (AMG-102) is a humanized monoclonal antibody directed against HGF, which interferes with the interaction between HGF and c-Met to prevent c-Met activation (PMID: 19649990, PMID: 31129386). |
DrugClasses | HGF Antibody 4 |
CAS Registry Number | 872514-65-3 |
NCIT ID | C67079 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Capecitabine + Cisplatin + Epirubicin + Rilotumumab | Capecitabine Cisplatin Epirubicin Rilotumumab | 0 | 0 |
Erlotinib + Rilotumumab | Erlotinib Rilotumumab | 0 | 1 |
Panitumumab + Rilotumumab | Panitumumab Rilotumumab | 0 | 0 |
Rilotumumab | Rilotumumab | 0 | 2 |